To compare the efficacy and safety profile of the original and biosimilar eculizumab in the treatment of pregnancy associated atypical hemolytic uremic syndrome (p-aHUS).
No takes yet. Share an insight, caveat, or question.
Korotchaeva et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: